PYC is not necessarily unique in trying to synthesise CPPs that...

PYC is not necessarily unique in trying to synthesise CPPs that are better than R9 and TAT - the information simply may not be out in public domain. There is plenty of academic evidence of people synthesising CPPs.

R9 is something I couldn't unearth much info about, but TAT is definitely in use in clinical trials. Some links below from my own personal notes.

Kai Pharmaceuticals (acquired by Amgen). Was working on CPP technology. Apparently this element of the research has been shelved. KAI-4169 almost commercialised.

http://www.businesswire.com/news/ho...aceuticals-Announces-Phase-1-Results-KAI-4169

http://www.genengnews.com/gen-news-...g-firm-kai-pharmaceuticals-for-315m/81246612/

KAI-9803 was delivered in animal model using a TAT CPP mechanism:
http://dmd.aspetjournals.org/content/39/10/1946.full

This article was a good intro to CPPs for me and also details more info on R9 and TAT and the Kai compounds:
http://www.degruyter.com/dg/viewart...e-3$002fejnm-2013-0005$002fejnm-2013-0005.xml


Cell Penetrating Peptides in the Delivery of Biopharmaceuticals
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030843/


Journal article on CPP use in cancer treatment (2015). Subscription required. The abstract suggests that the ability to increase the duration of action of CPPs will be a key benefit. This is something that PYC suggest they are good at.
http://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(15)00122-7


TAT is also being used for deliver anti HIV-1 drugs. In fact, TAT is derived from a protein associated with the HIV virus. It has got to at least Phase 2.
https://clinicaltrials.gov/ct2/show/NCT01513135
http://www.ncbi.nlm.nih.gov/pubmed/22336878
http://www.hiv1tat-vaccines.info/clinical_studies.htm
http://retrovirus.conferenceseries....e-1-clinical-trial-in-hiv-1-infected-patients